Antaros Medical, in collaboration with Sanofi, presents important data at the 53rd Annual Meeting of the European Association for the study of diabetes (EASD) on a first-in-class Glucagon (GCG) Positron Emission Tomography (PET) ligand, with suitable properties for clinical development targeting the glucagon receptor.